female |
43 (93.5%) |
median age |
37 (21-82) |
Re-vaccination status |
Re-vaccination status |
tolerated re-vaccination |
13 |
refered after 2nd. vaccination |
3 |
showed similar tolerability |
2 |
re-vaccination planned |
2 |
re-vaccination denied |
2 |
unknown status |
24 |
Diagnostic test |
Number of patients with positive
results |
SPT Comirnaty® |
1 |
IDT Comirnaty® |
2 |
SPT Vaxzervia® |
1 |
IDT Vaxzervia® |
0 |
SPT Spikevax® |
0 |
IDT Spikevax® |
1 |
IDT Janssen® |
0 |
SPT PEG2000 |
1 |
IDT PEG2000 |
4 |
SPT PEG6000 |
1 |
IDT PEG6000 |
2 |
SPT PS80 |
0 |
BAT - suspected SARS-Cov-2 vaccine |
3 |